A new research review published in Pediatric Neurology suggests that doctors may need to rethink how they talk about prognosis in primary mitochondrial diseases, such as thymidine kinase 2 deficiency (TK2d).
For decades, these disorders have often been described in stark terms, in part because most existing medical reports focus on the sickest patients and historically, few treatment options have been available. The authors argue that this picture is no longer complete.
The researchers note that more than 350 distinct primary mitochondrial diseases have now been identified, and outcomes vary widely depending on the specific gene involved, how much of the body is affected and how early treatment begins.
While serious complications such as respiratory failure and infections remain major risks, better seizure control, nutritional support and careful management of metabolic stress can influence outcomes for some patients.
The review highlights several mitochondrial disorders once associated with uniformly poor prognosis that can stabilize or even improve over time. While TK2d isn’t specifically discussed in the report, new therapies like oral deoxynucleosides have shown promising results, with studies reporting improved survival and motor function in many treated patients.
Learn more about TK2d treatment and care
The authors also revisit the long-held belief that people with primary mitochondrial diseases should not receive organ transplants, pointing to newer data suggesting that carefully selected patients can do just as well after transplant as other patients. They also note emerging research into treatments like gene therapy and mitochondrial augmentation therapy, which could one day further improve prognosis. The researchers caution that these therapies are still under study, but emphasize that the field is moving quickly.
Ultimately, the review calls for more individualized counseling that reflects both the seriousness of these diseases and the real progress being made.
“The bygone era of reflexively grim prognostication may indirectly limit access to hope or life-changing care,” the authors conclude. “Precision medicine in mitochondrial medicine, once an indomitable aspiration, is swiftly becoming standard of care, offering hope and conviction to patients and clinicians alike.”
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.